LAPTM4B Allele *2 Is a Marker of Poor Prognosis for Gallbladder Carcinoma

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhai, Guojun ^a   Yan, Kaowen ^b   Ji, Xiaoxu ^a   Xu, Wenrui ^b   Yang, Jiuling ^b   Xiong, Fuxia ^c   Su, Jing ^b   McNutt, Michael A ^b   Yang, Hua ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSOMAL PROTEIN TRANSMEMBRANE 4 BETA; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; LAPTM4B PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHI SQUARE TEST; CHOLECYSTECTOMY; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GALLBLADDER CARCINOMA; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; ALLELE; CHI SQUARE DISTRIBUTION; GALLBLADDER TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS;

ADULT; AGED; ALLELES; CHI-SQUARE DISTRIBUTION; FEMALE; GALLBLADDER NEOPLASMS; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866312965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045290     Document Type: Article

References (29)

1. Misra S, Chaturvedi A, Misra N, Sharma I, (2003) Carcinoma of the gallbladder. Lancet Oncology 4: 167-176.
2. Gabbi C, Kim H, Barros R, Korach-Andre M, Warner M, (2010) Gustafsson, Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc Natl Acad Sci 107: 14763-14768.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global Cancer statistics. CA Cancer J Clin 61: 69-90.
4. Matsumoto Y, Fujii H, Aoyama H, Yamamoto M, Suqahara K, et al. (1992) Surgical treatment of primary carcinoma of the gallbladder based on the histologic analysis of 48 surgical specimens. Am J Surg 163: 239-245.
5. Fong Y, Jarnagin W, Blumgart L, (2000) Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 232: 557-5.
6. Henson D, Albores-Saavedra J, Corle D, (1992) Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70: 1493-1497.
7. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, et al. (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22: 5060-5069.
8. Meng F, Song H, Luo C, Yin M, Xu Y, et al. (2011) Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 117: 2652-2658.
9. Meng F, Yin M, Song H, Yang H, Lou G, et al. (2010) LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 20: 745-750.
10. Yang H, Xiong F, Qi R, Liu Z, Lin M, et al. (2010) LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 101: 363-369.
11. Yang H, Xiong FX, Lin M, Yang Y, Nie X, et al. (2010) LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. Journal of cancer research and clinical oncology 136: 275-281.
12. Yang Y, Yang H, McNutt MA, Xiong F, Nie X, et al. (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20: 1077-1083.
13. Yin M, Lou C, Zhang W, Meng F, Zhang H, et al. (2012) LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer 22: 54-62.
14. Yin M, Xu Y, Lou G, Hou Y, Meng F, et al. (2011) LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 129: 629-635.
15. Zhou L, He XD, Chen J, Cui QC, Qu Q, et al. (2007) Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43: 809-815.
16. Zhou L, He XD, Cui QC, Zhou WX, Qu Q, et al. (2008) Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 264: 209-217.
17. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218.
18. Li L, Wei XH, Pan YP, Li HC, Yang H, et al. (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29: 5785-5795.
19. Zhou L, He XD, Yu JC, Zhou RL, Xiong FX, et al. (2010) Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepato-gastroenterology 57: 207-211.
20. Zhou L, He XD, Yu JC, Zhou RL, Yang H, et al. (2010) Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am j surg199: 515-521.
21. Liu X, Xiong F, Wei X, Yang H, Zhou R, (2009) LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer science 100: 2335-2340.
22. Yang H, Xiong F, Wei X, Yang Y, McNutt MA, et al. (2010) Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer letters 294: 236-244.
23. Wang S, Zhang QY, Zhou RL. (2011) Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol doi:doi: 10.1093/annonc/mdr538.
24. Cheng XJ, Xu W, Zhang QY, Zhou RL, (2008) Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 19: 527-532.
25. Liu Y, Zhang QY, Qian N, Zhou RL, (2007) Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 18: 311-316.
26. Zhai G, Yang H, Ji X, Xiong F, Su J, et al. (2011) Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Medl Oncol doi:doi: 10.1007/s12032-011-0139-y.
27. Yang H, Zhai G, Ji X, Xiong F, Su J, et al. (2011) Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol doi:doi: 10.1007/s12032-012-0173-4.
28. Yang H, Zhai G, Ji X, Xiong F, Su J, et al. (2012) LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One 4: e34984.
29. Lazcano-Ponce E, Miquel J, Munoz N, Herrero R, Ferrecio C, et al. (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349-364.